ISRCTN38972074 https://doi.org/10.1186/ISRCTN38972074

A Phase 1-2 Master Protocol to Study Intravenous ATTR-01 in Adult Participants with Select Epithelial Solid Tumours Under Multiple sub-protocols (ATTEST)

Submission date 22/08/2024	**Recruitment status** Recruiting	[X] Prospectively registered [_] Protocol [_] Statistical analysis plan [_] Results [_] Individual participant data [X] Record updated in last year
Registration date 29/01/2025	**Overall study status** Ongoing	
Last Edited 23/03/2026	**Condition category** Cancer	

Plain English summary of protocol

Background and study aims
This is a Phase 1-2 trial which is testing a new drug called ATTR-01 to find out if it may work to treat different types of cancer. ATTR-01 has not been approved as a medicine by any health authority.

What is ATTR-01 and how does it work?
ATTR-01 is a new drug designed to target cancer. ATTR-01 is made from a weakened adenovirus (Ad5). An Ad5 is a common human virus that causes cold like symptoms. Normally, an Ad5 will infect many cells in the body. ATTR-01 has been developed so that it should infect and only replicate (multiplies itself) in cancer cells. The drug is designed so that it does not kill healthy cells. This should make the drug better at killing cancer and cause fewer drug side effects. ATTR-01 is a type of immunotherapy (it stimulates the body's immune system). ATTR-01 is injected into a patient participants' blood stream. Once in the blood, ATTR-01 circulates and should infect cancer cells.
ATTR-01 may kill cancer cells in two ways:
1. Inside the cancer cell, ATTR-01 may force the cancer cell to make and release a potent (strong) drug. This drug can kill cancer cells by activating the body's immune system to fight the cancer.
2. ATTR-01 may kill cancer cells when the virus replicates (it bursts the cancer cell).

Who can use ATTR-01?
ATTR-01 has been developed to bind to a receptor (a type of 'hook') on cancer cells. Not all cancer types have this receptor on their surface. Only people with cancers that usually have this receptor may receive ATTR-01.

Who can participate?
Adult patients with solid epithelial tumours who meet the inclusion criteria.

What does the study involve?
Trial visits will take place at hospitals taking part in the trial. This may require more visits to the hospital than are usual for cancer care, but expenses will be paid for by Accession Therapeutics. A participant may be followed up for up to approximately five years in total. In the last four years, most follow-up can be as phone calls with the trial doctor. Participants can have other cancer treatments after ATTR-01, without having to leave trial follow-up. Participants can withdraw from the trial at any time, without giving any reason. Medical care or legal rights of a participant will not be affected if they choose to withdraw.
The trial will involve having tests and procedures to check health and find out about the cancer. The tests will include blood and urine samples, tumour biopsies and scans. Participants who receive ATTR-01 will have swabs to see how ATTR-01 leaves the body (mouth and rectal swabs). Accession Therapeutics will collect and use information (data) needed for the trial from the participants medical records and the samples they supply. Participant's data will be de-identified to protect their privacy (this means data is linked to a unique study code, and not the participant' s actual name). The data that is held by Accession Therapeutics will be safely and securely stored on databases that are managed by it and the companies that work for Accession Therapeutics.

What are the possible benefits and risks of participating?
This is the first time that ATTR-01 has been tested in humans. It is not yet known if the drug works or what the side effects may be. Participants that receive the drug may have mild cold-like symptoms, similar to receiving a vaccine. These could include fever, loss of appetite, tiredness, weakness, difficulty breathing, diarrhoea or inflamed bowel, feeling or being sick, skin changes (dryness, itching, rash), joint pains, urine infections and headaches. Taking part in a trial involves having more tests and hospital visits than in usual care. Taking part in research like this may not help you but may help other people with cancer in the future. There is no placebo drug in this trial.
It is not known if the virus may spread by sexual activity. The effect of ATTR-01 on unborn children or nursing infants is not known. For these reasons, participants must agree to the contraceptive requirements for the trial for up to a year after receiving the last dose of the drug.

Where is the study run from?
Accession Therapeutics Limited (UK)

When is the study starting and how long is it expected to run for?
August 2024 to December 2034

Who is funding the study?
Accession Therapeutics Limited (UK)

Who is the main contact?
Recruitment enquiries: clinicaloperations@accessiontherapeutics.com

Contact information

Type(s)
Scientific, Public

Contact name
Prof Hardev Pandha

Contact details

Building 7600c, The Quorum, Alec Issigonis Way, ARC Oxford
Oxford
United Kingdom
OX4 2JZ
+44 1865-950220
clinicaloperations@accessiontherapeutics.com

Type(s)
Principal investigator

Contact name
Prof Adel Samson

Contact details
Beckett Street
Leeds
United Kingdom
LS9 7TF
+44 113 2068362
adel.samson@nhs.net

Additional identifiers

Clinical Trials Information System (CTIS)
2024-516722-59-00

Integrated Research Application System (IRAS)
1010660

Central Portfolio Management System (CPMS)
57739

Protocol serial number
ATTR-01-01

Study information

Scientific Title
A Phase 1-2 Master Protocol to Study Intravenous ATTR-01 in Adult Participants with Select Epithelial Solid Tumours Under Multiple Sub-protocols (ATTEST)

Acronym
ATTEST

Study objectives
Master protocol primary objectives :
1. Primary: To evaluate the safety and tolerability of ATTR-01 in participants with select epithelial solid tumours.
2. To evaluate the anti-tumour activity of ATTR-01 in participants with select epithelial solid tumours.

3. To determine the optimal dose of ATTR-01 for further development of ATTR-01 in participants with select epithelial solid tumours.

Master protocol secondary objectives:
1. To evaluate the viral persistence and immunogenicity of ATTR-01 in participants with select epithelial solid tumours.
2. To further evaluate the anti-tumour activity of ATTR-01 in participants with select epithelial solid tumours.

Objectives may differ per sub-protocol.

Ethics approval required
Ethics approval required

Ethics approval(s)
Approved 30/12/2024, London - West London & GTAC Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 2071048075; westlondon.rec@hra.nhs.uk), ref: 24/LO/0686

Primary study design
Interventional

Study design
Interventional non randomized

Study type(s)
Efficacy, Safety

Health condition(s) or problem(s) studied
Select solid epithelial tumour; Pancreatic cancer; Lung cancer; Bladder cancer; Head and neck cancer; Endometrial cancer; Cholangiocarcinoma

Interventions
ATTR-01, the investigational medicinal product (IMP), is a Category 1/Biological Safety Level 1 genetically modified adenovirus type-5 (Ad5), which is targeted to specifically infect and replicate in tumour cells that express the protein alpha v beta 6 (αvβ6) integrin. ATTR-01 has been engineered to express a licensed anti-Programmed Death-Ligand 1 (PD-L1) human antibody cancer immune therapy, in cells expressing αvβ6 integrin. The proposed tumour types of participants to be enrolled in this study are epithelial solid tumours which typically demonstrate a high frequency (≥ 75%) of αvβ6 integrin expression.

The IMP is delivered intravenously. Multiple doses will be tested.

Trial ATTR-01-01 will study the IMP under a Master Protocol design whereby sub-protocol A is a first in human dose escalation.

The UK will only participate in sub-protocol A.

Intervention Type
Drug

Phase
Phase I/II

Drug/device/biological/vaccine name(s)
ATTR-01

Primary outcome(s)
Main Protocol (MP):
1. Incidence of adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), discontinuation of the investigational medicinal product(s) (IMP) due to toxicity and clinically significant alterations in vital signs or other clinical safety assessments
2. Objective Response Rate (ORR) from the first scan onwards, per RECIST V1.1
3. Duration of Response (DoR)

Key secondary outcome(s)
Main Protocol per RECIST V1.1 from the first scan onwards:
1. Disease Control Rate (DCR)
2. Time To Response (TTR)
3. Progression Free Survival (PFS)
4. Overall Survival (OS)
5. Maximum reduction in tumour size
Individual sub-protocols may have modified outcome measures

Completion date
31/12/2034

Eligibility

Key inclusion criteria
Main Protocol (MP): The following is applicable to all Sub-Protocols (SPs). Additional SP criteria may apply.
1. Consenting male and female adults (18 years of age) with select solid epithelial tumour indications known to have high frequency (75%) of αvβ6 integrin receptor expression as detailed in the applicable SP.
2. Received and failed/intolerant of Standard of Care (SoC) therapy where eligible (not including neoadjuvant).
3. Tumour lesion (not previously irradiated), suitable for safe pre- and post-treatment biopsies.
4. Measurable disease by Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1.
5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
6. Minimum life expectancy anticipated to be greater than three months
7. Willing to undertake appropriate measures of hygiene to prevent any spread of virus and protection of vulnerable individuals.
8. Adequate organ function.
9. Compliant with requirements for prior treatment washout and contraceptive measures applicable to genetically modified organisms (GMOs) and cancer therapies
10. Prior immune checkpoint antibody therapies as single agents or in combination with other anti-cancer agents is permissible.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Mixed

Lower age limit
18 Years

Upper age limit
99 Years

Sex
All

Total final enrolment
0

Key exclusion criteria
Master Protocol key exclusion criteria (additional sub-protocol specific criteria may apply):
1. Significant degree of fibrotic disease, including autoimmune diseases (e.g. systemic lupus, rheumatoid arthritis) or idiopathic and occupation-related pulmonary fibrosis.
2. Known prior history of intolerance to anti-programmed cell death protein 1 (PD-1) and/or anti-PD-L1 immunotherapy due to toxicity.
3. Has any of the comorbid conditions listed in the detailed exclusion criteria (MP or applicable SP).

Date of first enrolment
24/02/2025

Date of final enrolment
15/11/2029

Locations

Countries of recruitment
United Kingdom

England

Scotland

Wales

Spain

Study participating centre
St James University Hospital
Beckett Street

Bexley Wing
Leeds
England
LS9 7TF

Study participating centre
Churchill Hospital
Old Road
Headington
Oxford
England
OX3 7LE

Study participating centre
Velindre Cancer Centre
Velindre Road
Cardiff
Wales
CF14 2TL

Study participating centre
Beatson West of Scotland Cancer Centre
1053 Great Western Rd
Glasgow
Scotland
G61 1BD

Sponsor information

Organisation
Accession Therapeutics Limited

Funder(s)

Funder type
Industry

Funder Name

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated and/or analysed during this study will be included in the subsequent results publication

IPD sharing plan summary
Published as a supplement to the results publication